NeuExcell Therapeutics
State College
About NeuExcell Therapeutics
NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion. Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the power of gene therapy to restore damaged neural tissue.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $25.0M
- Funding stage: Seed
- Last round: Seed (May 2023)
- Website: neuexcell.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/neuexcell-therapeutics-70400 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.